2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Palliative Care, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Bacterial, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3343 Prior venetoclax exposure predicts dismal outcomes after gilteritinib failure in relapsed and refractory acute myeloid leukemia

Elizabeth Corley, MD, Brenden Bready, MS2, Andriy Derkach, PhD3, Jenna Ciervo, PharmD4, Richard Shin, PharmD5, Jacqueline Dela Pena, PharmD6, Ryan Daley, PharmD7, Richa Shah, PharmD, RPh8, Ali Kamali, PhD9, Xin Wang, MD, MSCE10, Kuo-Kai Chin, MD11, Baher Krayem, MD12, Gregory Goldgof, MD, PHD, MS13, Eytan M Stein I, MD14, Aaron D Goldberg, MD, PhD15
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Background:
Gilteritinib (gilt) is the only FDA-approved FLT3 inhibitor for relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). There are no standard treatment approaches for AML patients who relapse after gilt or who are refractory to gilt (gilt failure). Survival, molecular evolution, and response to treatments after gilt failure are poorly characterized.

Methods:
We conducted a single-center retrospective cohort study of R/R AML patients (pts) treated with gilt monotherapy at MSKCC (2016-2025). We screened 154 pts and excluded those who received multi-agent gilt regimens, prior gilt exposure, or gilt outside the R/R setting, leaving n=104. Gilt failure was defined as relapse after gilt or refractoriness to gilt. The failure timepoint was set at gilt discontinuation; for 3 pts who responded to gilt, underwent alloSCT, and relapsed, it was set at relapse after alloSCT. Overall survival (OS) was estimated from gilt start and from failure and compared by log-rank test.

Data were curated by chart review and the Hematologic Multimodal Analytics Platform (HeMAP), a large language model-enabled system (presented at EHA 2026; submitted separately to ASH 2026). All pts underwent manual chart review to confirm eligibility and correct derived variables.

Results:
Among 104 pts (median age 65 years [range 29-90]; 54 [52%] male; 77 [74%] White; de novo AML 62 [60%], secondary or therapy-related 42 [40%]; by ELN 2022, adverse 55 [53%], intermediate 41 [39%], favorable 8 [8%]), FLT3 was mutated at diagnosis in 60 (58%) and acquired at relapse in 38 (37%), with timing unknown in the remaining 6. All were FLT3-mutated at gilt start (FLT3-ITD 87, FLT3-TKD 11, ITD+TKD 4, and 2 non-canonical FLT3 variants). Pts had received a median of 1 prior line (range 0-6); 60 (58%) had prior venetoclax (ven), 61 (59%) intensive chemotherapy, 23 (22%) a prior FLT3 inhibitor, and 19 (18%) prior allogeneic stem cell transplant (alloSCT).

With a median follow-up of 53 mo (reverse Kaplan-Meier), 87 pts (84%) met our criteria for gilt failure (refractory, n=64; relapsed, n=23). The remaining 17 (16%) did not meet failure criteria: 10 (10%) remained in ongoing remission at cutoff and 7 died without relapse. At time of failure, FLT3 remained detectable in 60, was cleared in 19, and was unknown in 8.

Median OS was 7.4 mo (95% CI 5.4-9.5) from gilt start and 2.4 mo (1.5-4.3) from failure. Fifty-one pts (59%) received salvage therapy after gilt failure, most commonly ven-based (n=22, 43%). First-salvage response was CR/CRi/MLFS in 18 (35%); the other 33 (65%) had no response or were non-evaluable, and 6 proceeded to alloSCT. Salvage recipients had longer OS than the 36 without further therapy (6.9 [95% CI 4.3-10] vs 0.5 [0.3-0.8] mo).

Prior ven exposure predicted poorer response to salvage: 4 of 23 (17%) prior-ven pts achieved CR/CRi/MLFS (19 no response) vs 14 of 28 (50%) ven-naive pts (14 no response) (p=0.015). Prior ven also predicted poorer OS (2.5 mo [n=23] vs 9.3 mo [n=28]; p<0.001). The salvage regimen itself was not a significant predictor of OS (non-ven-based 4.3 vs ven-based 9.1 mo; p=0.2). FLT3 status alone at failure did not stratify OS (persistent 2.8 vs cleared 2.4 mo; p=0.3). However, integrating FLT3 clearance with ven exposure identified a salvageable subgroup: prior-ven pts (cleared or persistent FLT3) had only 2.5-2.8 mo median OS, while ven-naive pts who cleared FLT3 (n=5) had superior OS (34 mo [95% CI 18-NR]) vs 9.4 mo for FLT3-persistent/ven-naive pts (p=0.002).

On serial NGS, DNMT3A, NPM1, RUNX1, and TET2 were stable, whereas RAS-pathway mutations enriched from 26% at gilt start to 46% at failure and remained enriched after salvage (41%).

Conclusions:
Here we present the largest series to date reporting survival, salvage patterns, and molecular evolution anchored at the time of gilt failure. Clinical outcomes after gilt failure are generally poor (median OS ~2.4 mo), with no standard for subsequent therapy. This real-world study defines candidate determinants of post-gilt outcomes: prior ven exposure marks resistant disease, whereas pts who clear FLT3 and are ven-naive may represent a salvageable subgroup. Limitations of this study include the retrospective design and selection bias among salvage recipients. Integrating FLT3 clearance with ven history may guide optimal treatment sequencing after gilt and warrants prospective validation.

Elizabeth Corley, MD: No relevant conflicts of interest to declare.